SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Kenichi Hosonuma, Ken Sato, Yuichi Yamazaki, Masatoshi Yanagisawa, Hiroaki Hashizume, Norio Horiguchi, Satoru Kakizaki, Motoyasu Kusano, Masanobu Yamada, A Prospective Randomized Controlled Study of Long-Term Combination Therapy Using Ursodeoxycholic Acid and Bezafibrate in Patients With Primary Biliary Cirrhosis and Dyslipidemia, The American Journal of Gastroenterology, 2015, 110, 3, 423

    CrossRef

  2. 2
    Hani S Mousa, Ana Lleo, Pietro Invernizzi, Christopher L Bowlus, Merril Eric Gershwin, Advances in pharmacotherapy for primary biliary cirrhosis, Expert Opinion on Pharmacotherapy, 2015, 16, 5, 633

    CrossRef

  3. 3
    Akira Honda, Tadashi Ikegami, Yasushi Matsuzaki, Anti-gp210 and anti-centromere antibodies for the prediction of PBC patients with an incomplete biochemical response to UDCA and bezafibrate, Hepatology Research, 2015, 45, 8
  4. 4
    Atsushi Tanaka, Junko Hirohara, Yasuni Nakanuma, Hirohito Tsubouchi, Hajime Takikawa, Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA, Journal of Gastroenterology, 2015, 50, 6, 675

    CrossRef

  5. 5
    Yan Zhang, Kan Chen, Weiqi Dai, Yujing Xia, Fan Wang, Miao Shen, Ping Cheng, Chengfen Wang, Jing Yang, Rong Zhu, Huawei Zhang, Jingjing Li, Yuanyuan Zheng, Junshan Wang, Jie Lu, Yingqun Zhou, Chuanyong Guo, Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis, Hepatology Research, 2015, 45, 1
  6. 6
    Alla Y. Grigorian, Houssam E. Mardini, Christophe Corpechot, Raoul Poupon, Cynthia Levy, Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis, Clinics and Research in Hepatology and Gastroenterology, 2015, 39, 3, 296

    CrossRef

  7. 7
    Nisanne S. Ghonem, David N. Assis, James L. Boyer, Fibrates and cholestasis, Hepatology, 2015, 62, 2
  8. 8
    Raoul Poupon, Liver alkaline phosphatase: A missing link between choleresis and biliary inflammation, Hepatology, 2015, 61, 6
  9. 9
    Lori WE van der Schoor, Henkjan J Verkade, Folkert Kuipers, Johan W Jonker, New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition, Expert Opinion on Drug Metabolism & Toxicology, 2015, 11, 2, 273

    CrossRef

  10. 10
    Ulrich Beuers, Michael Trauner, Peter Jansen, Raoul Poupon, New paradigms in the treatment of hepatic cholestasis: From UDCA to FXR, PXR and beyond, Journal of Hepatology, 2015, 62, 1, S25

    CrossRef

  11. 11
    Annarosa Floreani, Irene Franceschet, Lisa Perini, Nora Cazzagon, M. Eric Gershwin, Christopher L. Bowlus, New Therapies for Primary Biliary Cirrhosis, Clinical Reviews in Allergy & Immunology, 2015, 48, 2-3, 263

    CrossRef

  12. 12
    Konstantinos N. Lazaridis, Nicholas F. LaRusso, The Cholangiopathies, Mayo Clinic Proceedings, 2015, 90, 6, 791

    CrossRef

  13. 13
    Marco Carbone, James M. Neuberger, Autoimmune liver disease, autoimmunity and liver transplantation, Journal of Hepatology, 2014, 60, 1, 210

    CrossRef

  14. 14
    Sabela Lens, María Leoz, Leyla Nazal, Miguel Bruguera, Albert Parés, Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid, Liver International, 2014, 34, 2
  15. 15
    Gernot Zollner, Michael Trauner, Cholestase – Update 2014, Wiener klinische Wochenschrift Education, 2014, 8, 3-4, 73

    CrossRef

  16. 16
    Anna Baghdasaryan, Peter Chiba, Michael Trauner, Clinical application of transcriptional activators of bile salt transporters, Molecular Aspects of Medicine, 2014, 37, 57

    CrossRef

  17. 17
    Frans J.C. Cuperus, Emina Halilbasic, Michael Trauner, Fibrate treatment for primary biliary cirrhosis, Current Opinion in Gastroenterology, 2014, 30, 3, 279

    CrossRef

  18. You have free access to this content18
    Guidelines for the management of primary biliary cirrhosis, Hepatology Research, 2014, 44,
  19. 19
    Pietro Invernizzi, M. Eric Gershwin, New therapeutics in primary biliary cirrhosis: will there ever be light?, Liver International, 2014, 34, 2
  20. 20
    Kidist K Yimam, Christopher L Bowlus, Obeticholic acid for the treatment of primary biliary cirrhosis, Expert Opinion on Orphan Drugs, 2014, 2, 12, 1351

    CrossRef

  21. 21
    Cyril Bigo, Jenny Kaeding, Diala El Husseini, Iwona Rudkowska, Mélanie Verreault, Marie Claude Vohl, Olivier Barbier, PPARα: A Master Regulator of Bilirubin Homeostasis, PPAR Research, 2014, 2014, 1

    CrossRef

  22. 22
    Avegail Flores, Marlyn J. Mayo, Primary biliary cirrhosis in 2014, Current Opinion in Gastroenterology, 2014, 30, 3, 245

    CrossRef

  23. You have free access to this content23
    T. H. Karlsen, M. Vesterhus, K. M. Boberg, Review article: controversies in the management of primary biliary cirrhosis and primary sclerosing cholangitis, Alimentary Pharmacology & Therapeutics, 2014, 39, 3
  24. 24
    Qiuyang Zhang, Wei Yang, Hanlin Song, Hui Wu, Yang Lu, Jiake He, Di Zhao, Xijing Chen, Tissue distribution and ontogeny of multidrug resistance protein 2, a phosphatidylcholine translocator, in rats, European Journal of Drug Metabolism and Pharmacokinetics, 2014,

    CrossRef

  25. 25
    Raoul Poupon, Christophe Corpechot, Treatment of primary biliary cirrhosis, Expert Opinion on Orphan Drugs, 2014, 2, 1, 11

    CrossRef

  26. You have free access to this content26
    Albert Parés, Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid?, Clinical Liver Disease, 2014, 3, 2
  27. 27
    Nisanne S. Ghonem, James L. Boyer, Fibrates as adjuvant therapy for chronic cholestatic liver disease: Its time has come, Hepatology, 2013, 57, 5